Phase II Study of Docetaxel, Oxaliplatin, Capecitabine With Bevacizumab and Trastuzumab in Case of Human Epidermal Growth Factor Receptor 2 (HER2)-Positivity in Patients With Locally Advanced or Metastatic Gastric Cancer or Adenocarcinoma of the Gastro-oesophageal Junction (B-DOCT Study).

Trial Profile

Phase II Study of Docetaxel, Oxaliplatin, Capecitabine With Bevacizumab and Trastuzumab in Case of Human Epidermal Growth Factor Receptor 2 (HER2)-Positivity in Patients With Locally Advanced or Metastatic Gastric Cancer or Adenocarcinoma of the Gastro-oesophageal Junction (B-DOCT Study).

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Docetaxel (Primary) ; Oxaliplatin (Primary) ; Trastuzumab (Primary)
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms B-DOCT
  • Most Recent Events

    • 11 Mar 2016 Results published in the Cancer
    • 17 Mar 2012 Planned end date (19 Jan 2015) added as reported by European Clinical Trials Database.
    • 17 Mar 2012 Actual initiation date (19 Jan 2011) and planned patients number (80) added as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top